



## Clinical trial results:

### A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

#### Summary

EudraCT number	2007-006717-17
Trial protocol	GB
Global end of trial date	27 August 2015

#### Results information

Result version number	v1 (current)
This version publication date	09 September 2016
First version publication date	09 September 2016

#### Trial information

##### Trial identification

Sponsor protocol code	13923
-----------------------	-------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00721162
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Alias: I4T-IE-JVBR, Trial Number: 13923

Notes:

#### Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis/IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	27 August 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	27 August 2015
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

The purpose of this study is to determine if ramucirumab given as monotherapy is effective in the treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.

Protection of trial subjects:

This study was conducted in accordance with International Code of Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 August 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects****Subjects enrolled per country**

Country: Number of subjects enrolled	United States: 56
Country: Number of subjects enrolled	United Kingdom: 4
Worldwide total number of subjects	60
EEA total number of subjects	4

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	36
From 65 to 84 years	24
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

73 participants signed informed consent.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Ramucirumab
------------------	-------------

Arm description:

Ramucirumab at 8 milligrams/kilogram (mg/kg) administered intravenously over 1 hour every other week (every 14 days) of a 28-day cycle.

Arm type	Experimental
Investigational medicinal product name	Ramucirumab
Investigational medicinal product code	
Other name	IMC-1121B
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.

<b>Number of subjects in period 1</b>	Ramucirumab
Started	60
Received any amount of study drug	60
Completed	60

## Baseline characteristics

### Reporting groups

Reporting group title	Ramucirumab
-----------------------	-------------

Reporting group description:

Ramucirumab at 8 milligrams/kilogram (mg/kg) administered intravenously over 1 hour every other week (every 14 days) of a 28-day cycle.

Reporting group values	Ramucirumab	Total	
Number of subjects	60	60	
Age Categorical			
All participants who received any amount of study drug.			
Units: years			
<=18 years	0	0	
Between 18 and 65 years	36	36	
>=65 years	24	24	
Gender, Male/Female			
All participants who received any amount of study drug.			
Units: participants			
Female	60	60	
Male	0	0	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1	1	
Not Hispanic or Latino	59	59	
Unknown or Not Reported	0	0	
Race/Ethnicity, Customized			
Units: Subjects			
Black or African American	5	5	
White	52	52	
Other	3	3	
Region of Enrollment			
Units: Subjects			
United States	56	56	
United Kingdom	4	4	

## End points

### End points reporting groups

Reporting group title	Ramucirumab
Reporting group description: Ramucirumab at 8 milligrams/kilogram (mg/kg) administered intravenously over 1 hour every other week (every 14 days) of a 28-day cycle.	

### Primary: Progression-Free survival at 6 months (PFS-6)

End point title	Progression-Free survival at 6 months (PFS-6) <sup>[1]</sup>
End point description: Data presented are the percentage of participants without progressive disease (PD) or death from any cause at 6 month after first dose. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is $\geq 20\%$ increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion.	
End point type	Primary
End point timeframe: First dose to 6 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Unable to provide statistical analysis for single-arm study with no comparison group due to system limitations.

End point values	Ramucirumab			
Subject group type	Reporting group			
Number of subjects analysed	60			
Units: percentage of participants				
number (confidence interval 95%)	25 (14.7 to 37.9)			

### Statistical analyses

No statistical analyses for this end point

### Primary: Objective response rate (ORR)

End point title	Objective response rate (ORR) <sup>[2]</sup>
End point description: Objective response is confirmed complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. CR is disappearance of all target and non-target lesions; PR is $\geq 30\%$ decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesion. ORR is calculated as a total number of participants with CR or PR from the start of study treatment until disease progression/recurrence or the start of new therapeutic anticancer treatment, whichever occurred first, divided by the total number of participants treated, then multiplied by 100.	
End point type	Primary
End point timeframe: First dose to date of objective progressive disease /death or new anti-cancer therapy up to 34.6 months	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Unable to provide statistical analysis for single-arm study with no comparison group due to system limitations.

<b>End point values</b>	Ramucirumab			
Subject group type	Reporting group			
Number of subjects analysed	60			
Units: percentage of participants				
number (confidence interval 95%)	5 (1 to 13.9)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Progression-Free survival (PFS)

End point title	Progression-Free survival (PFS)
-----------------	---------------------------------

End point description:

Defined as the time from date of first dose to the first observation of progression of disease (PD) or death due to any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is  $\geq 20\%$  increase in sum of longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or new lesion. For participants who had no PD or death or had started new therapeutic anticancer treatment, PFS was censored at their last radiographic tumor assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

First dose to measured progressive disease or death due to any cause up to 34.6 months

<b>End point values</b>	Ramucirumab			
Subject group type	Reporting group			
Number of subjects analysed	60			
Units: months				
median (confidence interval 95%)	3.5 (2.3 to 5.3)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall survival at 1 year (OS-1)

End point title	Overall survival at 1 year (OS-1)
-----------------	-----------------------------------

End point description:

Data presented are the percentage of participants surviving at least 12 months after first dose based on Kaplan Meier Method.

End point type	Secondary
----------------	-----------

End point timeframe:  
First dose to 12 months

<b>End point values</b>	Ramucirumab			
Subject group type	Reporting group			
Number of subjects analysed	60			
Units: percentage of participants				
number (confidence interval 95%)	48 (34.9 to 59.9)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description: Overall survival is defined as the time from first dose to the date of death due to any cause. For participants who were alive or were lost to follow-up, overall survival was censored on the last date the participant was known to be alive.	
End point type	Secondary
End point timeframe: First dose to death due to any cause up to 43.9 months	

<b>End point values</b>	Ramucirumab			
Subject group type	Reporting group			
Number of subjects analysed	60			
Units: months				
median (confidence interval 95%)	11.1 (8.3 to 17)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Summary Listing of Participants Reporting Drug-Related Treatment-Emergent Adverse Events

End point title	Summary Listing of Participants Reporting Drug-Related Treatment-Emergent Adverse Events
End point description: Data presented are the number of participants who experienced treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or 4 TEAE, or adverse events (AE) leading to discontinuation of treatment that were considered to be related to ramucirumab. A summary of SAEs	

and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.

End point type	Secondary
End point timeframe:	
First dose to 30 months	

<b>End point values</b>	Ramucirumab			
Subject group type	Reporting group			
Number of subjects analysed	60			
Units: participants				
number (not applicable)				
Related TEAE	56			
Related SAE	10			
Related Grade 3 or 4 TEAE	21			
Related AE leading to discontinuation	4			

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Entire Study

Adverse event reporting additional description:

I4T-IE-JVBR

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.0
--------------------	------

### Reporting groups

Reporting group title	Ramucirumab 8 mg/kg
-----------------------	---------------------

Reporting group description: -

Serious adverse events	Ramucirumab 8 mg/kg		
Total subjects affected by serious adverse events			
subjects affected / exposed	22 / 60 (36.67%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
neoplasm progression			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	4 / 60 (6.67%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 4		
Vascular disorders			
deep vein thrombosis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
abscess sterile			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
hernia obstructive			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
oedema peripheral			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
pyrexia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
female genital tract fistula			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
dyspnoea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
pleural effusion			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Investigations</b>			
alanine aminotransferase increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 60 (3.33%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
aspartate aminotransferase increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
hepatic enzyme increased			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Injury, poisoning and procedural complications</b>			
expired drug administered			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 60 (5.00%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac disorders</b>			
mitral valve incompetence			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Nervous system disorders</b>			
neuralgia			

alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
thrombocytopenia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
ascites			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
gastritis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
intestinal perforation			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	2 / 60 (3.33%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 1		
nausea			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
rectal haemorrhage			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
small intestinal obstruction			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	3 / 60 (5.00%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
vomiting			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
renal failure acute			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
peritonitis			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
postoperative wound infection			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
sepsis			
alternative dictionary used: MedDRA 16.0			

subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
hypercalcaemia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
hypokalaemia			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	1 / 60 (1.67%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Ramucirumab 8 mg/kg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	58 / 60 (96.67%)		
Vascular disorders			
flushing			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	5 / 60 (8.33%)		
occurrences (all)	6		
hypertension			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	16 / 60 (26.67%)		
occurrences (all)	19		
General disorders and administration site conditions			
chills			
alternative dictionary used: MedDRA 16.0			
subjects affected / exposed	5 / 60 (8.33%)		
occurrences (all)	8		

<p>fatigue</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>41 / 60 (68.33%)</p> <p>72</p>		
<p>oedema peripheral</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>16 / 60 (26.67%)</p> <p>23</p>		
<p>pyrexia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>8 / 60 (13.33%)</p> <p>11</p>		
<p>Reproductive system and breast disorders</p> <p>vaginal haemorrhage</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 60 (6.67%)</p> <p>6</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>cough</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dysphonia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dyspnoea</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>epistaxis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>13 / 60 (21.67%)</p> <p>14</p> <p>6 / 60 (10.00%)</p> <p>7</p> <p>12 / 60 (20.00%)</p> <p>15</p> <p>8 / 60 (13.33%)</p> <p>15</p>		

oropharyngeal pain alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	5 / 60 (8.33%) 5		
Psychiatric disorders insomnia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	7 / 60 (11.67%) 7		
Investigations alanine aminotransferase increased alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)  aspartate aminotransferase increased alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)  weight decreased alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	4 / 60 (6.67%) 7  4 / 60 (6.67%) 11  9 / 60 (15.00%) 13		
Nervous system disorders dizziness alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)  dysgeusia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)  headache alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	7 / 60 (11.67%) 8  4 / 60 (6.67%) 4  43 / 60 (71.67%) 72		



<p>Blood and lymphatic system disorders</p> <p>anaemia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>thrombocytopenia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>11 / 60 (18.33%)</p> <p>21</p> <p>6 / 60 (10.00%)</p> <p>20</p>		
<p>Gastrointestinal disorders</p> <p>abdominal discomfort</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>abdominal distension</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>abdominal pain</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>abdominal pain lower</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>constipation</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>diarrhoea</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dyspepsia</p>	<p>4 / 60 (6.67%)</p> <p>4</p> <p>7 / 60 (11.67%)</p> <p>7</p> <p>12 / 60 (20.00%)</p> <p>14</p> <p>5 / 60 (8.33%)</p> <p>5</p> <p>13 / 60 (21.67%)</p> <p>15</p> <p>21 / 60 (35.00%)</p> <p>41</p>		

<p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 60 (10.00%)</p> <p>8</p>		
<p>gastrooesophageal reflux disease</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 60 (6.67%)</p> <p>4</p>		
<p>gingival bleeding</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 60 (10.00%)</p> <p>10</p>		
<p>nausea</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>26 / 60 (43.33%)</p> <p>38</p>		
<p>stomatitis</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>11 / 60 (18.33%)</p> <p>15</p>		
<p>vomiting</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>20 / 60 (33.33%)</p> <p>31</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>alopecia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>pruritus</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 60 (8.33%)</p> <p>5</p> <p>4 / 60 (6.67%)</p> <p>4</p>		
Renal and urinary disorders			

proteinuria alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	8 / 60 (13.33%) 10		
Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)  back pain alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)  joint swelling alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)  muscular weakness alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)  myalgia alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)  pain in extremity alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)	12 / 60 (20.00%) 18  9 / 60 (15.00%) 13  6 / 60 (10.00%) 7  4 / 60 (6.67%) 4  7 / 60 (11.67%) 9  8 / 60 (13.33%) 11		
Infections and infestations nasopharyngitis alternative dictionary used: MedDRA 16.0 subjects affected / exposed occurrences (all)  sinusitis	4 / 60 (6.67%) 6		

<p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 60 (6.67%)</p> <p>4</p>		
<p>upper respiratory tract infection</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 60 (6.67%)</p> <p>5</p>		
<p>urinary tract infection</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>13 / 60 (21.67%)</p> <p>19</p>		
<p>Metabolism and nutrition disorders</p> <p>decreased appetite</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>hyperglycaemia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>hypoalbuminaemia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>hypomagnesaemia</p> <p>alternative dictionary used: MedDRA 16.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>12 / 60 (20.00%)</p> <p>16</p> <p>7 / 60 (11.67%)</p> <p>8</p> <p>5 / 60 (8.33%)</p> <p>5</p> <p>6 / 60 (10.00%)</p> <p>6</p>		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported